Pertussis toxin

Last updated
Pertussis toxin, subunit 1
Pertussis toxin complex.png
The crystal structure of pertussis toxin, [1]
Identifiers
SymbolPertussis_S1
Pfam PF02917
InterPro IPR003898
SCOP2 1bcp / SCOPe / SUPFAM
Available protein structures:
Pfam   structures / ECOD  
PDB RCSB PDB; PDBe; PDBj
PDBsum structure summary
Pertussis toxin, subunit 2 and 3
Identifiers
SymbolPertussis_S2S3
Pfam PF02918
InterPro IPR003899
SCOP2 1bcp / SCOPe / SUPFAM
Available protein structures:
Pfam   structures / ECOD  
PDB RCSB PDB; PDBe; PDBj
PDBsum structure summary
Pertussis toxin, subunit 4
Identifiers
SymbolPertus-S4-tox
Pfam PF09275
InterPro IPR015355
SCOP2 1prt / SCOPe / SUPFAM
Available protein structures:
Pfam   structures / ECOD  
PDB RCSB PDB; PDBe; PDBj
PDBsum structure summary
Pertussis toxin, subunit 5
Identifiers
SymbolPertus-S5-tox
Pfam PF09276
InterPro IPR015356
SCOP2 1prt / SCOPe / SUPFAM
Available protein structures:
Pfam   structures / ECOD  
PDB RCSB PDB; PDBe; PDBj
PDBsum structure summary

Pertussis toxin (PT) is a protein-based AB5-type exotoxin produced by the bacterium Bordetella pertussis , [2] which causes whooping cough. PT is involved in the colonization of the respiratory tract and the establishment of infection. [3] Research suggests PT may have a therapeutic role in treating a number of common human ailments, including hypertension, [4] viral infection, [5] and autoimmunity. [6] [7] [8]

Contents

History

PT clearly plays a central role in the pathogenesis of pertussis although this was discovered only in the early 1980s. The appearance of pertussis is quite recent, compared with other epidemic infectious diseases. The earliest mention of pertussis, or whooping cough, is of an outbreak in Paris in 1414. This was published in Moulton's The Mirror of Health, in 1640. Another epidemic of pertussis took place in Paris in 1578 and was described by a contemporary observer, Guillaume de Baillou. Pertussis was well known throughout Europe by the middle of the 18th century. Jules Bordet and Octave Gengou described in 1900 the finding of a new “ovoid bacillus” in the sputum of a 6-month-old infant with whooping cough. They were also the first to cultivate Bordetella pertussis at the Pasteur Institute in Brussels in 1906. [9]

One difference between the different species of Bordetella is that B. pertussis produces PT and the other species do not. Bordetella parapertussis shows the most similarity to B. pertussis and was therefore used for research determining the role of PT in causing the typical symptoms of whooping cough. Rat studies showed the development of paroxysmal coughing, a characteristic for whooping cough, occurred in rats infected with B. pertussis. Rats infected with B. parapertussis or a PT-deficient mutant of B. pertussis did not show this symptom; neither of these two strains produced PT. [10]

Structure

A large group of bacterial exotoxins are referred to as "A/B toxins", in essence because they are formed from two subunits. [11] The "A" subunit possesses enzyme activity, and is transferred to the host cell following a conformational change in the membrane-bound transport "B" subunit. [11] Pertussis toxin is an exotoxin with six subunits (named S1 through S5—each complex contains two copies of S4). [12] [13] The subunits are arranged in A-B structure: the A component is enzymatically active and is formed from the S1 subunit, while the B component is the receptor-binding portion and is made up of subunits S2–S5. [13] The subunits are encoded by ptx genes encoded on a large PT operon that also includes additional genes that encode Ptl proteins. Together, these proteins form the PT secretion complex. [14]

Mechanism of pathogenesis

PT is released from B. pertussis in an inactive form. Following PT binding to a cell membrane receptor, it is taken up in an endosome, after which it undergoes retrograde transport to the trans-Golgi network and endoplasmic reticulum. [15] At some point during this transport, the A subunit (or protomer) becomes activated, perhaps through the action of glutathione and ATP. [12] [16] PT catalyzes the ADP-ribosylation of the αi subunits of the heterotrimeric G protein. This prevents the G proteins from interacting with G protein-coupled receptors on the cell membrane, thus interfering with intracellular communication. [17] The Gi subunits remain locked in their GDP-bound, inactive state, thus unable to inhibit adenylate cyclase activity, leading to increased cellular concentrations of cAMP.

Increased intracellular cAMP affects normal biological signaling. The toxin causes several systemic effects, among which is an increased release of insulin, causing hypoglycemia. Whether the effects of pertussis toxin are responsible for the paroxysmal cough remains unknown. [18]

As a result of this unique mechanism, PT has also become widely used as a biochemical tool to ADP-ribosylate GTP-binding proteins in the study of signal transduction. [1] It has also become an essential component of new acellular vaccines. [1]

Effects on the immune system

PT has been shown to affect the innate immune response. It inhibits the early recruitment of neutrophils and macrophages, and interferes with early chemokine production and neutrophil chemotaxis. [19] Chemokines are signalling molecules produced by infected cells and attract neutrophils and macrophages. Neutrophil chemotaxis is thought to be disrupted by inhibiting G-protein-coupled chemokine receptors by the ADP-ribosylation of Gi proteins. [20]

Because of the disrupted signalling pathways, synthesis of chemokines will be affected. This will prevent the infected cell from producing them and thereby inhibiting recruitment of neutrophils. Under normal circumstances, alveolar macrophages and other lung cells produce a variety of chemokines. PT has been found to inhibit the early transcription of keratinocyte-derived chemokine, macrophage inflammatory protein 2 and LPS-induced CXC chemokine. [20] Eventually, PT causes lymphocytosis, one of the systemic manifestations of whooping cough. [21]

PT, a decisive virulence determinant of B. pertussis, is able to cross the blood–brain barrier by increasing its permeability. [22] As a result, PT can cause severe neurological complications; however, recently it has been found that the medicinal usage of Pertussis toxin can promote the development of regulatory T cells and prevent central nervous system autoimmune disease, such as multiple sclerosis. [23]

Metabolism

PT is known to dissociate into two parts in the endoplasmic reticulum (ER): the enzymatically active A subunit (S1) and the cell-binding B subunit. The two subunits are separated by proteolic cleavage. The B subunit will undergo ubiquitin-dependent degradation by the 26S proteasome. However, the A subunit lacks lysine residues, which are essential for ubiquitin-dependent degradation. Therefore, PT subunit A will not be metabolized like most other proteins. [24]

PT is heat-stable and protease-resistant, but once the A and B are separated, these properties change. The B subunit will stay heat-stable at temperatures up to 60 °C, but it is susceptible to protein degradation. PT subunit A, on the other hand, is less susceptible to ubiquitin-dependent degradation, but is unstable at temperature of 37 °C. This facilitates unfolding of the protein in the ER and tricks the cell into transporting the A subunit to the cytosol, where normally unfolded proteins will be marked for degradation. So, the unfolded conformation will stimulate the ERAD-mediated translocation of PT A into the cytosol. Once in the cytosol, it can bind to NAD and form a stable, folded protein again. Being thermally unstable is also the Achilles heel of PT subunit A. As always, there is an equilibrium between the folded and unfolded states. When the protein is unfolded, it is susceptible to degradation by the 20S proteasome, which can degrade only unfolded proteins. [24]

PT and vaccines

Since the introduction of pertussis vaccines in the 1940s and 1950s, different genetic changes have been described surrounding the pertussis toxin.

Emergence of ptxP3

ptxP is the pertussis toxin's promoter gene. There is a well documented emergence and global spread of ptxP3 strains evolving from and replacing the native ptxP1 strains, [25] associated with an increased production of the toxin, and thus an increased virulence. [26] Such spread has been documented in multiple countries, and sometimes but not always linked to the resurgence of pertussis in the end of the 20th century. Countries with a documented spread of ptxP3 include Australia, [26] [27] Denmark, [28] Finland, [29] Iran, [30] Italy, [31] Japan, [32] the Netherlands, [33] and Sweden. [34]

See also

Related Research Articles

<span class="mw-page-title-main">Whooping cough</span> Human disease caused by the bacteria Bordetella pertussis

Whooping cough, also known as pertussis or the 100-day cough, is a highly contagious, vaccine-preventable bacterial disease. Initial symptoms are usually similar to those of the common cold with a runny nose, fever, and mild cough, but these are followed by two or three months of severe coughing fits. Following a fit of coughing, a high-pitched whoop sound or gasp may occur as the person breathes in. The violent coughing may last for 10 or more weeks, hence the phrase "100-day cough". The cough may be so hard that it causes vomiting, rib fractures, and fatigue. Children less than one year old may have little or no cough and instead have periods where they cannot breathe. The incubation period is usually seven to ten days. Disease may occur in those who have been vaccinated, but symptoms are typically milder.

<span class="mw-page-title-main">Acute bronchitis</span> Medical condition

Acute bronchitis, also known as a chest cold, is short-term bronchitis – inflammation of the bronchi of the lungs. The most common symptom is a cough. Other symptoms include coughing up mucus, wheezing, shortness of breath, fever, and chest discomfort. The infection may last from a few to ten days. The cough may persist for several weeks afterward with the total duration of symptoms usually around three weeks. Some have symptoms for up to six weeks.

<span class="mw-page-title-main">Exotoxin</span> Toxin from bacteria that destroys or disrupts cells

An exotoxin is a toxin secreted by bacteria. An exotoxin can cause damage to the host by destroying cells or disrupting normal cellular metabolism. They are highly potent and can cause major damage to the host. Exotoxins may be secreted, or, similar to endotoxins, may be released during lysis of the cell. Gram negative pathogens may secrete outer membrane vesicles containing lipopolysaccharide endotoxin and some virulence proteins in the bounding membrane along with some other toxins as intra-vesicular contents, thus adding a previously unforeseen dimension to the well-known eukaryote process of membrane vesicle trafficking, which is quite active at the host–pathogen interface.

<i>Bordetella bronchiseptica</i> Species of bacterium

Bordetella bronchiseptica is a small, gram-negative, rod-shaped bacterium of the genus Bordetella. It can cause infectious bronchitis in dogs and other animals, but rarely infects humans. Closely related to B. pertussis—the obligate human pathogen that causes pertussis ; B. bronchiseptica can persist in the environment for extended periods.

<span class="mw-page-title-main">DPT vaccine</span> Combination vaccine

The DPT vaccine or DTP vaccine is a class of combination vaccines against three infectious diseases in humans: diphtheria, pertussis, and tetanus (lockjaw). The vaccine components include diphtheria and tetanus toxoids, and either killed whole cells of the bacterium that causes pertussis or pertussis antigens. The term toxoid refers to vaccines which use an inactivated toxin produced by the pathogen which they are targeted against to generate an immune response. In this way, the toxoid vaccine generates an immune response which is targeted against the toxin which is produced by the pathogen and causes disease, rather than a vaccine which is targeted against the pathogen itself. The whole cells or antigens will be depicted as either "DTwP" or "DTaP", where the lower-case "w" indicates whole-cell inactivated pertussis and the lower-case "a" stands for "acellular". In comparison to alternative vaccine types, such as live attenuated vaccines, the DTP vaccine does not contain any live pathogen, but rather uses inactivated toxoid to generate an immune response; therefore, there is not a risk of use in populations that are immune compromised since there is not any known risk of causing the disease itself. As a result, the DTP vaccine is considered a safe vaccine to use in anyone and it generates a much more targeted immune response specific for the pathogen of interest.

<span class="mw-page-title-main">Pertactin</span> Virulence factor of Bordetella pertussis

In molecular biology, pertactin (PRN) is a highly immunogenic virulence factor of Bordetella pertussis, the bacterium that causes pertussis. Specifically, it is an outer membrane protein that promotes adhesion to tracheal epithelial cells. PRN is purified from Bordetella pertussis and is used for the vaccine production as one of the important components of acellular pertussis vaccine.

<i>Bordetella</i> Genus of bacteria

Bordetella is a genus of small, Gram-negative, coccobacilli bacteria of the phylum Pseudomonadota. Bordetella species, with the exception of B. petrii, are obligate aerobes, as well as highly fastidious, or difficult to culture. All species can infect humans. The first three species to be described ; are sometimes referred to as the 'classical species'. Two of these are also motile.

Adhesins are cell-surface components or appendages of bacteria that facilitate adhesion or adherence to other cells or to surfaces, usually in the host they are infecting or living in. Adhesins are a type of virulence factor.

<i>Bordetella pertussis</i> Species of bacterium causing pertussis or whooping cough

Bordetella pertussis is a Gram-negative, aerobic, pathogenic, encapsulated coccobacillus bacterium of the genus Bordetella, and the causative agent of pertussis or whooping cough. Its virulence factors include pertussis toxin, adenylate cyclase toxin, filamentous hæmagglutinin, pertactin, fimbria, and tracheal cytotoxin.

<span class="mw-page-title-main">Cholera toxin</span> Protein complex secreted by the bacterium Vibrio cholerae

Cholera toxin is an AB5 multimeric protein complex secreted by the bacterium Vibrio cholerae. CTX is responsible for the massive, watery diarrhea characteristic of cholera infection. It is a member of the heat-labile enterotoxin family.

Adenylate cyclase toxin is a virulence factor produced by some members of the genus Bordetella. Together with the pertussis toxin it is the most important virulence factor of the causative agent of whooping cough, Bordetella pertussis. Bordetella bronchiseptica and Bordetella parapertussis, also able to cause pertussis-like symptoms, also produce adenylate cyclase toxin. It is a toxin secreted by the bacteria to influence the host immune system.

<i>Bordetella parapertussis</i> Species of bacterium

Bordetella parapertussis is a small Gram-negative bacterium of the genus Bordetella that is adapted to colonise the mammalian respiratory tract. Pertussis caused by B. parapertussis manifests with similar symptoms to B. pertussis-derived disease, but in general tends to be less severe. Immunity derived from B. pertussis does not protect against infection by B. parapertussis, however, because the O-antigen is found only on B. parapertussis. This antigen protects B. parapertussis against antibodies specific to B. pertussis, so the bacteria are free to colonize the host's lungs without being subject to attack by previous antibodies. These findings suggest B. parapertussis evolved in a host population that had already developed immunity to B. pertussis, where being able to evade B. pertussis immunity was an advantage.

The AB5 toxins are six-component protein complexes secreted by certain pathogenic bacteria known to cause human diseases such as cholera, dysentery, and hemolytic–uremic syndrome. One component is known as the A subunit, and the remaining five components are B subunits. All of these toxins share a similar structure and mechanism for entering targeted host cells. The B subunit is responsible for binding to receptors to open up a pathway for the A subunit to enter the cell. The A subunit is then able to use its catalytic machinery to take over the host cell's regular functions.

Gi protein alpha subunit is a family of heterotrimeric G protein alpha subunits. This family is also commonly called the Gi/o family or Gi/o/z/t family to include closely related family members. G alpha subunits may be referred to as Gi alpha, Gαi, or Giα.

<span class="mw-page-title-main">Pertussis vaccine</span> Vaccine protecting against whooping cough

Pertussis vaccine is a vaccine that protects against whooping cough (pertussis). There are two main types: whole-cell vaccines and acellular vaccines. The whole-cell vaccine is about 78% effective while the acellular vaccine is 71–85% effective. The effectiveness of the vaccines appears to decrease by between 2 and 10% per year after vaccination with a more rapid decrease with the acellular vaccines. The vaccine is only available in combination with tetanus and diphtheria vaccines. Pertussis vaccine is estimated to have saved over 500,000 lives in 2002.

Microbial toxins are toxins produced by micro-organisms, including bacteria, fungi, protozoa, dinoflagellates, and viruses. Many microbial toxins promote infection and disease by directly damaging host tissues and by disabling the immune system. Endotoxins most commonly refer to the lipopolysaccharide (LPS) or lipooligosaccharide (LOS) that are in the outer plasma membrane of Gram-negative bacteria. The botulinum toxin, which is primarily produced by Clostridium botulinum and less frequently by other Clostridium species, is the most toxic substance known in the world. However, microbial toxins also have important uses in medical science and research. Currently, new methods of detecting bacterial toxins are being developed to better isolate and understand these toxins. Potential applications of toxin research include combating microbial virulence, the development of novel anticancer drugs and other medicines, and the use of toxins as tools in neurobiology and cellular biology.

The RTX toxin superfamily is a group of cytolysins and cytotoxins produced by bacteria. There are over 1000 known members with a variety of functions. The RTX family is defined by two common features: characteristic repeats in the toxin protein sequences, and extracellular secretion by the type I secretion systems (T1SS). The name RTX refers to the glycine and aspartate-rich repeats located at the C-terminus of the toxin proteins, which facilitate export by a dedicated T1SS encoded within the rtx operon.

Adenylate cyclase toxin (CyaA) is released from bacterium Bordetella pertussis by the T1SS and released in the host’s respiratory tract in order to suppress its early innate and subsequent adaptive immune defense.

<span class="mw-page-title-main">Tracheal cytotoxin</span> Chemical compound

Tracheal cytotoxin (TCT) is a 921 dalton glycopeptide released by Bordetella pertussis, Vibrio fischeri, and Neisseria gonorrhoeae. It is a soluble piece of peptidoglycan (PGN) found in the cell wall of all gram-negative bacteria, but only some bacteria species release TCT due to inability to recycle this piece of anhydromuropeptide.

Whole-cell vaccines are a type of vaccine that has been prepared in the laboratory from entire cells. Such vaccines simultaneously contain multiple antigens to activate the immune system. They induce antigen-specific T-cell responses.

References

  1. 1 2 3 Stein PE, Boodhoo A, Armstrong GD, Cockle SA, Klein MH, Read RJ (January 1994). "The crystal structure of pertussis toxin". Structure. 2 (1): 45–57. doi: 10.1016/S0969-2126(00)00007-1 . PMID   8075982.
  2. ↑ Ryan KJ, Ray CG, eds. (2004). Sherris Medical Microbiology (4th ed.). McGraw Hill. ISBN   0-8385-8529-9.
  3. ↑ Carbonetti NH, Artamonova GV, Mays RM, Worthington ZE (November 2003). "Pertussis Toxin Plays an Early Role in Respiratory Tract Colonization by Bordetella pertussis". Infect. Immun. 71 (11): 6358–66. doi:10.1128/IAI.71.11.6358-6366.2003. PMC   219603 . PMID   14573656.
  4. ↑ Kost C, Herzer W, Li P, Jackson E (1999). "Pertussis toxin-sensitive G-proteins and regulation of blood pressure in the spontaneously hypertensive rat". Clin Exp Pharmacol Physiol. 26 (5–6): 449–55. doi:10.1046/j.1440-1681.1999.03058.x. PMID   10386237. S2CID   12902466.
  5. ↑ Alfano M, Pushkarsky T, Poli G, Bukrinsky M (2000). "The B-Oligomer of Pertussis Toxin Inhibits Human Immunodeficiency Virus Type 1 Replication at Multiple Stages". J Virol. 74 (18): 8767–70. doi:10.1128/JVI.74.18.8767-8770.2000. PMC   116391 . PMID   10954581.
  6. ↑ Bagley K, Abdelwahab S, Tuskan R, Fouts T, Lewis G (2002). "Pertussis toxin and the adenylate cyclase toxin from Bordetella pertussis activate human monocyte-derived dendritic cells and dominantly inhibit cytokine production through a cAMP-dependent pathway". J Leukoc Biol. 72 (5): 962–9. doi:10.1189/jlb.72.5.962. PMID   12429718. S2CID   16457655.
  7. ↑ Locht C, Keith JM (1986). "Pertussis toxin gene: nucleotide sequence and genetic organization". Science. 232 (4755): 1258–1264. Bibcode:1986Sci...232.1258L. doi:10.1126/science.3704651. PMID   3704651.
  8. ↑ Rappuoli R, Nicosia A, Perugini M, Franzini C, Casagli MC, Borri MG, Antoni G, Almoni M, Neri P, Ratti G (1986). "Cloning and sequencing of the pertussis toxin genes: operon structure and gene duplication". Proc. Natl. Acad. Sci. U.S.A. 83 (13): 4631–4635. Bibcode:1986PNAS...83.4631N. doi: 10.1073/pnas.83.13.4631 . PMC   323795 . PMID   2873570.
  9. ↑ Cherry JD (March 2007). "Historical Perspective on Pertussis and Use of Vaccines to Prevent It". Microbe Magazine. Archived from the original on 2011-06-23.
  10. ↑ Parton R (June 1999). "Review of the biology of Bordetella pertussis". Biologicals. 27 (2): 71–6. doi:10.1006/biol.1999.0182. PMID   10600186.
  11. 1 2 Gibert M, Perelle S, Boquet P, Popoff MR (1993). "Characterization of Clostridium perfringens iota-toxin genes and expression in Escherichia coli". Infect. Immun. 61 (12): 5147–5156. doi:10.1128/IAI.61.12.5147-5156.1993. PMC   281295 . PMID   8225592.
  12. 1 2 Kaslow HR, Burns DL (June 1992). "Pertussis toxin and target eukaryotic cells: binding, entry, and activation". FASEB J. 6 (9): 2684–90. doi: 10.1096/fasebj.6.9.1612292 . PMID   1612292. S2CID   20607696.
  13. 1 2 Locht C, Antoine R (1995). "A proposed mechanism of ADP-ribosylation catalyzed by the pertussis toxin S1 subunit". Biochimie. 77 (5): 333–40. doi:10.1016/0300-9084(96)88143-0. PMID   8527486.
  14. ↑ Weiss A, Johnson F, Burns D (1993). "Molecular characterization of an operon required for pertussis toxin secretion". Proc Natl Acad Sci U S A. 90 (7): 2970–4. Bibcode:1993PNAS...90.2970W. doi: 10.1073/pnas.90.7.2970 . PMC   46218 . PMID   8464913.
  15. ↑ Plaut RD, Carbonetti NH (May 2008). "Retrograde transport of pertussis toxin in the mammalian cell". Cell. Microbiol. 10 (5): 1130–9. doi: 10.1111/j.1462-5822.2007.01115.x . PMID   18201245. S2CID   22900943.
  16. ↑ Finger H, von Koenig CH (1996). "Bordetella". In Barron S, et al. (eds.). Barron's Medical Microbiology (4th ed.). Univ of Texas Medical Branch. ISBN   0-9631172-1-1. PMID   21413270.
  17. ↑ Burns D (1988). "Subunit structure and enzymic activity of pertussis toxin". Microbiol Sci. 5 (9): 285–7. PMID   2908558.
  18. ↑ Carbonetti NH (2010). "Pertussis toxin and adenylate cyclase toxin: key virulence factors of Bordetella pertussis and cell biology tools". Future Microbiol. 5 (3): 455–69. doi:10.2217/fmb.09.133. PMC   2851156 . PMID   20210554.
  19. ↑ Bestebroer J, De Haas CJ, Van Strijp JA (2010). "How microorganisms avoid phagocyte attraction". FEMS Microbiology Reviews. 34 (3): 395–414. doi: 10.1111/j.1574-6976.2009.00202.x . PMID   20059549.
  20. 1 2 Andreasen, C. & Carbonetti, N.H. (2008). "Pertussis Toxin Inhibits Early Chemokine Production To Delay Neutrophil Recruitment in Response to Bordetella pertussis Respiratory Tract Infection in Mice". Infection and Immunity. 76 (11): 5139–5148. doi:10.1128/IAI.00895-08. PMC   2573337 . PMID   18765723.
  21. ↑ Cherry, J.D.; Baraff, LJ; Hewlett, E (1989). "The past, present, and future of pertussis. The role of adults in epidemiology and future control". Western Journal of Medicine. 150 (3): 319–328. PMC   1026455 . PMID   2660414.
  22. ↑ Kügler S, Böcker K, Heusipp G, Greune L, Kim KS, Schmidt MA (March 2007). "Pertussis toxin transiently affects barrier integrity, organelle organization and transmigration of monocytes in a human brain microvascular endothelial cell barrier model". Cell. Microbiol. 9 (3): 619–32. doi:10.1111/j.1462-5822.2006.00813.x. PMID   17002784. S2CID   6747379.
  23. ↑ Weber MS, Benkhoucha M, Lehmann-Horn K, et al. (2010). Unutmaz D (ed.). "Repetitive Pertussis Toxin Promotes Development of Regulatory T Cells and Prevents Central Nervous System Autoimmune Disease". PLOS ONE. 5 (12): e16009. Bibcode:2010PLoSO...516009W. doi: 10.1371/journal.pone.0016009 . PMC   3012729 . PMID   21209857.
  24. 1 2 Pande AH, Moe D, Jamnadas M, Tatulian SA, Teter K (2006). "The Pertussis Toxin S1 Subunit Is a Thermally Unstable Protein Susceptible to Degradation by the 20S Proteasome". Biochemistry. 45 (46): 13734–40. doi:10.1021/bi061175+. PMC   2518456 . PMID   17105192.
  25. ↑ Lam, Connie; Octavia, Sophie; Bahrame, Zahra; Sintchenko, Vitali; Gilbert, Gwendolyn L.; Lan, Ruiting (March 2012). "Selection and emergence of pertussis toxin promoter ptxP3 allele in the evolution of Bordetella pertussis". Infection, Genetics and Evolution. 12 (2): 492–495. Bibcode:2012InfGE..12..492L. doi:10.1016/j.meegid.2012.01.001. PMID   22293463.
  26. 1 2 Mooi, Frits R.; van Loo, Inge H.M.; van Gent, Marjolein; He, Qiushui; Bart, Marieke J.; Heuvelman, Kees J.; de Greeff, Sabine C.; Diavatopoulos, Dimitri; Teunis, Peter; Nagelkerke, Nico; Mertsola, Jussi (2009). "Bordetella pertussis Strains with Increased Toxin Production Associated with Pertussis Resurgence". Emerging Infectious Diseases. 15 (8): 1206–1213. doi: 10.3201/eid1508.081511 . ISSN   1080-6040. PMC   2815961 . PMID   19751581. S2CID   18101684.
  27. ↑ Lam, Connie; Octavia, Sophie; Ricafort, Lawrence; Sintchenko, Vitali; Gilbert, Gwendolyn L.; Wood, Nicholas; McIntyre, Peter; Marshall, Helen; Guiso, Nicole; Keil, Anthony D.; Lawrence, Andrew (April 2014). "Rapid Increase in Pertactin-deficient Bordetella pertussis Isolates, Australia". Emerging Infectious Diseases. 20 (4): 626–633. doi:10.3201/eid2004.131478. ISSN   1080-6040. PMC   3966384 . PMID   24655754.
  28. ↑ Petersen, Randi Føns; Dalby, Tine; Dragsted, Ditte Marie; Mooi, Frits; Lambertsen, Lotte (May 2012). "Temporal Trends in Bordetella pertussis Populations, Denmark, 1949–2010". Emerging Infectious Diseases. 18 (5): 767–774. doi:10.3201/eid1805.110812. ISSN   1080-6040. PMC   3358084 . PMID   22515990.
  29. ↑ Kallonen, T.; Mertsola, J.; Mooi, F.R.; He, Q. (October 2012). "Rapid detection of the recently emerged Bordetella pertussis strains with the ptxP3 pertussis toxin promoter allele by real-time PCR". Clinical Microbiology and Infection. 18 (10): E377–E379. doi: 10.1111/j.1469-0691.2012.04000.x . PMID   22909320.
  30. ↑ Safarchi, Azadeh; Saedi, Samaneh; Octavia, Sophie; Sedaghatpour, Mehdi; Bolourchi, Negin; Tay, Chin Yen; Lamichhane, Binit; Shahcheraghi, Fereshteh; Lan, Ruiting (September 2021). "Evolutionary genomics of recent clinical Bordetella pertussis isolates from Iran: wide circulation of multiple ptxP3 lineages and report of the first ptxP3 filamentous hemagglutinin-negative B. pertussis". Infection, Genetics and Evolution. 93: 104970. Bibcode:2021InfGE..9304970S. doi:10.1016/j.meegid.2021.104970. PMID   34171476.
  31. ↑ Loconsole, Daniela; De Robertis, Anna Lisa; Morea, Anna; Metallo, Angela; Lopalco, Pier Luigi; Chironna, Maria (May 2018). "Resurgence of Pertussis and Emergence of the Ptxp3 Toxin Promoter Allele in South Italy". Pediatric Infectious Disease Journal. 37 (5): e126–e131. doi: 10.1097/INF.0000000000001804 . ISSN   0891-3668. PMID   28945679. S2CID   205692275.
  32. ↑ Zomer, Aldert; Otsuka, Nao; Hiramatsu, Yukihiro; Kamachi, Kazunari; Nishimura, Naoko; Ozaki, Takao; Poolman, Jan; Geurtsen, Jeroen (2018-05-01). "Bordetella pertussis population dynamics and phylogeny in Japan after adoption of acellular pertussis vaccines". Microbial Genomics. 4 (5). doi: 10.1099/mgen.0.000180 . ISSN   2057-5858. PMC   5994715 . PMID   29771235.
  33. ↑ van Gent, Marjolein; Bart, Marieke J.; van der Heide, Han G. J.; Heuvelman, Kees J.; Mooi, Frits R. (2012-09-28). Hozbor, Daniela Flavia (ed.). "Small Mutations in Bordetella pertussis Are Associated with Selective Sweeps". PLOS ONE. 7 (9): e46407. Bibcode:2012PLoSO...746407V. doi: 10.1371/journal.pone.0046407 . ISSN   1932-6203. PMC   3460923 . PMID   23029513.
  34. ↑ Advani, Abdolreza; Gustafsson, Lennart; Åhrén, Christina; Mooi, Frits R.; Hallander, Hans O (April 2011). "Appearance of Fim3 and ptxP3-Bordetella pertussis strains, in two regions of Sweden with different vaccination programs". Vaccine. 29 (18): 3438–3442. doi:10.1016/j.vaccine.2011.02.070. PMID   21396900.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.